EA201591283A1 - Количественная оценка эффективности кэп матричной рнк - Google Patents

Количественная оценка эффективности кэп матричной рнк

Info

Publication number
EA201591283A1
EA201591283A1 EA201591283A EA201591283A EA201591283A1 EA 201591283 A1 EA201591283 A1 EA 201591283A1 EA 201591283 A EA201591283 A EA 201591283A EA 201591283 A EA201591283 A EA 201591283A EA 201591283 A1 EA201591283 A1 EA 201591283A1
Authority
EA
Eurasian Patent Office
Prior art keywords
efficiency
cep
quantitative estimation
matrix rna
mrna
Prior art date
Application number
EA201591283A
Other languages
English (en)
Inventor
Майкл Хартлейн
Франк Дероза
Ануша Диаз
Original Assignee
Шир Хьюман Дженетик Терапис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шир Хьюман Дженетик Терапис, Инк. filed Critical Шир Хьюман Дженетик Терапис, Инк.
Publication of EA201591283A1 publication Critical patent/EA201591283A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6823—Release of bound markers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение предоставляет, помимо прочего, способы количественной оценки эффективности кэпирования мРНК, в особенности мРНК, синтезированной in vitro. В некоторых вариантах осуществления способы включают хроматографические способы количественного определения эффективности кэпирования мРНК и статуса метилирования кэпов.
EA201591283A 2013-03-14 2014-03-14 Количественная оценка эффективности кэп матричной рнк EA201591283A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784337P 2013-03-14 2013-03-14
PCT/US2014/027587 WO2014152659A1 (en) 2013-03-14 2014-03-14 Quantitative assessment for cap efficiency of messenger rna

Publications (1)

Publication Number Publication Date
EA201591283A1 true EA201591283A1 (ru) 2016-02-29

Family

ID=50639965

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591283A EA201591283A1 (ru) 2013-03-14 2014-03-14 Количественная оценка эффективности кэп матричной рнк

Country Status (13)

Country Link
US (3) US9970047B2 (ru)
EP (1) EP2971102B8 (ru)
JP (1) JP2016514970A (ru)
CN (1) CN105051213A (ru)
AU (1) AU2014239250A1 (ru)
BR (1) BR112015022505A2 (ru)
CA (1) CA2903487A1 (ru)
DK (1) DK2971102T3 (ru)
EA (1) EA201591283A1 (ru)
ES (1) ES2680595T3 (ru)
MX (1) MX2015011944A (ru)
TR (1) TR201811157T4 (ru)
WO (1) WO2014152659A1 (ru)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600616A (en) 2009-12-01 2014-11-28 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
KR102128248B1 (ko) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
DK2718269T3 (en) 2011-06-08 2018-04-09 Translate Bio Inc SPLITLY LIPIDS
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
AU2014239264A1 (en) 2013-03-14 2015-08-27 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger RNA
DK2968586T3 (en) 2013-03-14 2018-10-08 Translate Bio Inc CFTR MRNA COMPOSITIONS AND RELATED PROCEDURES AND APPLICATIONS
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015061500A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for argininosuccinate synthetase deficiency
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
SG11201604198YA (en) * 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
EP3090060B1 (en) 2013-12-30 2019-02-20 CureVac AG Methods for rna analysis
JP6571679B2 (ja) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
WO2017001058A1 (en) * 2015-07-01 2017-01-05 Curevac Ag Method for analysis of an rna molecule
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
ES2862412T3 (es) 2015-10-14 2021-10-07 Translate Bio Inc Modificación de enzimas relacionados con el ARN para producción mejorada
US20210108252A1 (en) 2015-12-09 2021-04-15 Novartis Ag Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017149139A1 (en) * 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis
US20190167811A1 (en) 2016-04-13 2019-06-06 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
SI3458083T1 (sl) 2016-05-18 2023-03-31 Modernatx, Inc. Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba
IL266501B2 (en) 2016-11-10 2024-06-01 Translate Bio Inc An improved ICE-based lipid nanoparticle formulation for delivery of mRNA
AU2018224318B2 (en) 2017-02-27 2024-06-20 Translate Bio, Inc. Methods for purification of messenger RNA
US10808241B2 (en) 2017-02-27 2020-10-20 Translate Bio, Inc. Methods for purification of messenger RNA
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
AU2018224325B2 (en) 2017-02-27 2024-05-02 Translate Bio, Inc. Large scale synthesis of messenger RNA
MA49138A (fr) 2017-05-16 2020-03-25 Translate Bio Inc Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
AU2019325702A1 (en) 2018-08-24 2021-02-25 Translate Bio, Inc. Methods for purification of messenger RNA
EP3877538A1 (en) 2018-11-08 2021-09-15 Translate Bio, Inc. Methods and compositions for messenger rna purification
EP3883592A1 (en) 2018-11-21 2021-09-29 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
US20220040281A1 (en) 2018-12-21 2022-02-10 Curevac Ag Rna for malaria vaccines
EP3899034A1 (en) 2018-12-21 2021-10-27 CureVac AG Methods for rna analysis
WO2020168466A1 (en) 2019-02-19 2020-08-27 Stemirna Therapeutics Co., Ltd. Modified nucleoside and synthetic methods thereof
EP3956303A1 (en) 2019-04-18 2022-02-23 Translate Bio, Inc. Cystine cationic lipids
ES2972014T3 (es) 2019-04-22 2024-06-10 Translate Bio Inc Lípidos catiónicos de tioéster
US20220257724A1 (en) 2019-05-03 2022-08-18 Translate Bio, Inc. Di-thioester cationic lipids
US11453877B2 (en) 2019-05-15 2022-09-27 Translate Bio, Inc. Methods for purification of messenger RNA
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
CA3144457A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Tricine and citric acid lipids
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
WO2021021988A1 (en) 2019-07-30 2021-02-04 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
BR112022001947A2 (pt) 2019-08-14 2022-09-20 Curevac Ag Combinações e composições de rna com propriedades imunoestimuladoras reduzidas
CN114729369A (zh) * 2019-08-29 2022-07-08 苏黎世大学 最小mRNA及其用途
MX2022003394A (es) 2019-09-20 2022-06-22 Translate Bio Inc Arnm que codifica cftr manipulado.
WO2021072172A1 (en) 2019-10-09 2021-04-15 Translate Bio, Inc. Compositions, methods and uses of messenger rna
JP2022553042A (ja) 2019-10-21 2022-12-21 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの組成物、方法および使用
CN115461042A (zh) 2019-12-20 2022-12-09 翻译生物公司 制备负载mrna的脂质纳米颗粒的改进方法
IL294073A (en) 2019-12-20 2022-08-01 Translate Bio Inc Rectal administration of messenger rna
CN116113430A (zh) 2020-02-04 2023-05-12 奎尔法克股份有限公司 冠状病毒疫苗
CN115443338A (zh) 2020-02-10 2022-12-06 翻译生物公司 用于信使rna纯化的方法和组合物
JP2023513836A (ja) 2020-02-18 2023-04-03 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａのインビトロ転写プロセスの改善
AU2021226578A1 (en) 2020-02-25 2022-10-20 Translate Bio, Inc. Improved processes of preparing mRNA-loaded lipid nanoparticles
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
WO2021226461A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Generation of optimized nucleotide sequences
EP4146680A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
AU2021269042A1 (en) 2020-05-07 2023-02-02 Translate Bio, Inc. Optimized nucleotide sequences encoding SARS-CoV-2 antigens
EP4146342A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Improved compositions for cftr mrna therapy
WO2021231901A1 (en) 2020-05-15 2021-11-18 Translate Bio, Inc. Lipid nanoparticle formulations for mrna delivery
CN116322758A (zh) 2020-05-29 2023-06-23 库尔维科欧洲股份公司 基于核酸的组合疫苗
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
CN112111558A (zh) * 2020-08-19 2020-12-22 翌圣生物科技（上海）有限公司 一种测定牛痘病毒加帽酶活性的方法
EP4157344A2 (en) 2020-08-31 2023-04-05 CureVac SE Multivalent nucleic acid based coronavirus vaccines
WO2022072836A2 (en) 2020-10-01 2022-04-07 Translate Bio, Inc. Methods for purification of messenger rna
AU2021358777A1 (en) 2020-10-06 2023-06-15 Translate Bio, Inc. Improved process and formulation of lipid nanoparticles
WO2022081544A1 (en) 2020-10-12 2022-04-21 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
US20220133631A1 (en) 2020-10-12 2022-05-05 Translate Bio, Inc. Process of preparing ice-based lipid nanoparticles
US20220136022A1 (en) 2020-10-15 2022-05-05 Translate Bio, Inc. Large Scale Synthesis of Messenger RNA
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
US20220160633A1 (en) 2020-11-09 2022-05-26 Translate Bio, Inc. Compositions for delivery of codon-optimized mrna
EP4251129A1 (en) 2020-11-25 2023-10-04 Translate Bio, Inc. Stable liquid lipid nanoparticle formulations
CA3171051A1 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022155404A1 (en) 2021-01-14 2022-07-21 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022204549A1 (en) 2021-03-25 2022-09-29 Translate Bio, Inc. Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
CA3212653A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4330427A1 (en) 2021-04-29 2024-03-06 Translate Bio, Inc. Methods for measuring poly a tail length
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
EP4347875A1 (en) * 2021-06-04 2024-04-10 Translate Bio, Inc. Assay for quantitative assessment of mrna capping efficiency
CA3224175A1 (en) 2021-06-18 2022-12-22 Sanofi Multivalent influenza vaccines
EP4388090A1 (en) 2021-08-16 2024-06-26 Translate Bio, Inc. Screening codon-optimized nucleotide sequences
AU2022336664A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
US20230302112A1 (en) 2021-11-05 2023-09-28 Sanofi Respiratory synctial virus rna vaccine
AU2022388747A1 (en) 2021-11-10 2024-06-20 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2023102373A1 (en) 2021-11-30 2023-06-08 Sanofi Pasteur Inc. Human metapneumovirus vaccines
WO2023111262A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
CN114250268A (zh) * 2021-12-23 2022-03-29 北京毅新博创生物科技有限公司 检测mRNA样品的加帽效率的产品及用途
WO2023115495A1 (zh) * 2021-12-23 2023-06-29 北京毅新博创生物科技有限公司 质谱法检测mRNA加帽效率的方法
CN114894916A (zh) * 2022-04-02 2022-08-12 翌圣生物科技(上海)股份有限公司 一种检测rna加帽效率的方法
WO2023201161A1 (en) * 2022-04-15 2023-10-19 Thermo Finnigan Llc Method for quantitative monitoring of mrna capping efficiency
TW202408567A (zh) 2022-05-06 2024-03-01 法商賽諾菲公司 用於核酸疫苗之訊息序列
CN114574466B (zh) * 2022-05-09 2022-08-02 翌圣生物科技(上海)股份有限公司 一种嵌合加帽酶及其制备方法与应用
JP2023181989A (ja) 2022-06-13 2023-12-25 上海臻上医薬科技有限公司 マイクロニードル注射製剤およびその使用
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
GB202209732D0 (en) * 2022-07-01 2022-08-17 Sintef Tto As Method of analysing rna
US20240043826A1 (en) 2022-07-29 2024-02-08 Sanofi Methods for ethanol-free mrna purification
WO2024044108A1 (en) 2022-08-22 2024-02-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against coronaviruses
WO2024064732A2 (en) 2022-09-20 2024-03-28 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b-antibodies
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination
WO2024094876A1 (en) 2022-11-04 2024-05-10 Sanofi Methods for messenger rna tailing
WO2024104914A1 (en) 2022-11-14 2024-05-23 BioNTech SE Rna capping efficiency assay
WO2024112652A1 (en) 2022-11-21 2024-05-30 Translate Bio, Inc. Compositions of dry powder formulations of messenger rna and methods of use thereof
WO2024126809A1 (en) 2022-12-15 2024-06-20 Sanofi Mrna encoding influenza virus-like particle
WO2024126847A1 (en) 2022-12-15 2024-06-20 Sanofi Mrna recombinant capping enzymes
CN116426610B (zh) * 2023-06-08 2024-01-05 启辰生生物科技(珠海)有限公司 一种LC-MS法准确定量mRNA加帽效率的方法
CN116590382B (zh) * 2023-07-12 2023-11-10 上海奥浦迈生物科技股份有限公司 检测mRNA样品加帽率的探针、试剂盒及其使用方法
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
DE4140463A1 (de) 1991-12-09 1993-06-17 Boehringer Mannheim Gmbh 2'-desoxy-isoguanosin, dessen isostere analoge sowie anwendung derselben
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US5268289A (en) 1991-12-27 1993-12-07 Epicentre Technologies Corp. Thermostable ribonuclease H
US5459055A (en) 1991-12-27 1995-10-17 Epicentre Technologies Corporation Thermostable ribonuclease H isolated from Thermus flavus
CN1231695A (zh) 1996-08-16 1999-10-13 同和药品工业株式会社 HBV聚合酶,起源于HBV聚合酶的RNaseH,其制备过程和在筛选抗病毒剂中的应用
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6043060A (en) 1996-11-18 2000-03-28 Imanishi; Takeshi Nucleotide analogues
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
EP2341058A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
JP2001525166A (ja) 1997-12-04 2001-12-11 アイシス・ファーマシューティカルス・インコーポレーテッド ヒトｒｎａｓｅｈおよびその組成物および使用
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
US6001652A (en) 1998-09-18 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of cREL expression
JP4202646B2 (ja) 1999-08-30 2008-12-24 ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アザプリン化合物及びその使用
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
CA2437558A1 (en) * 2001-01-31 2002-08-08 The Board Of Regents Of The University Of Texas System Method and apparatus for the confinement of materials in a micromachined chemical sensor array
JP2009544754A (ja) 2006-07-28 2009-12-17 アプライド バイオシステムズ， エルエルシー ジヌクレオチドｍｒｎａキャップアナログ
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
US9017970B2 (en) * 2008-05-02 2015-04-28 Cellscript, Llc RNA polyphosphatase compositions, kits, and uses thereof
US20100035249A1 (en) 2008-08-05 2010-02-11 Kabushiki Kaisha Dnaform Rna sequencing and analysis using solid support
WO2012135805A2 (en) * 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
AU2014239264A1 (en) 2013-03-14 2015-08-27 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger RNA
WO2017149139A1 (en) 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis

Also Published As

Publication number Publication date
US20180291425A1 (en) 2018-10-11
CN105051213A (zh) 2015-11-11
US20160032356A1 (en) 2016-02-04
JP2016514970A (ja) 2016-05-26
BR112015022505A2 (pt) 2017-10-24
ES2680595T3 (es) 2018-09-10
WO2014152659A1 (en) 2014-09-25
MX2015011944A (es) 2015-12-01
US11365437B2 (en) 2022-06-21
EP2971102A1 (en) 2016-01-20
US20220364145A1 (en) 2022-11-17
EP2971102B8 (en) 2018-08-15
TR201811157T4 (tr) 2018-08-27
DK2971102T3 (en) 2018-08-27
EP2971102B1 (en) 2018-06-20
US9970047B2 (en) 2018-05-15
AU2014239250A1 (en) 2015-08-27
CA2903487A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
EA201591283A1 (ru) Количественная оценка эффективности кэп матричной рнк
EA201591286A1 (ru) Количественная оценка эффективности кэп матричной рнк
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
EA201591961A1 (ru) Ингибиторы акк и их применение
IL243752A0 (en) Multispecific antibodies, preparations containing them and their uses
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
UY34885A (es) Proteínas de unión anti-mesotelina
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201592223A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA SERPINAl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR112016005957A2 (pt) detecção de alvo multiaptâmero
EA201591962A1 (ru) Ингибиторы акк и их применение
DK3317415T3 (da) UTR'er, som forøger translationseffektiviteten for RNA-molekyler
GB2537077A (en) Methods for sequencing nucleic acids
CL2015001516A1 (es) Compuestos derivados de piridopirazinas sustituidas, inhibidores de syk; composicion farmaceutica; metodo para tratar una enfermedad inflamatoria, alergias, enfermedad autoinmune, enfermedad proliferativa celular, entre otras.
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
UY34473A (es) Ensayo de alto rendimiento de polimorfismo de nucleótido simple
TWD180369S (zh) 無儲水桶式逆滲透淨水器
CL2017002829A1 (es) Sistemas y métodos para reducir las corrientes parásitas no deseadas.